Lexaria BioScience (OTC: LXRP-CSE: LXX) CEO Chris Bunka joined Steve Darling from Proactive Vancouver on Skype with news the company has signed a licensing deal for their DehydraTech technology with Cannadips from Humboldt, California.
Bunka telling Proactive this is a massive deal for the company that will see products in roughly 5000 stores across the U.S. and will have more retail locations selling Lexaria product that all the legal cannabis dispensaries across North America combined.
CSE:LXX
Market: CSE
Market Cap: $52.47 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...
The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...
1 week, 5 days ago
2 min read
Prev article
2 min read